Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
48,932,355
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
18,632,401
-
Shares change
-
-591,017
-
Total reported value, excl. options
-
$703,886,639
-
Value change
-
-$18,569,388
-
Put/Call ratio
-
33.8%
-
Number of buys
-
63
-
Number of sells
-
-82
-
Price
-
$37.78
Significant Holders of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) as of Q4 2021
214 filings reported holding AXSM - Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2021.
Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18,632,401 shares
of 48,932,355 outstanding shares and own 38.1% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (2,685,622 shares), BlackRock Inc. (2,109,622 shares), RTW INVESTMENTS, LP (1,618,819 shares), ALETHEA CAPITAL MANAGEMENT, LLC (1,123,929 shares), Avidity Partners Management LP (775,000 shares), STATE STREET CORP (745,907 shares), Bellevue Group AG (651,937 shares), BAKER BROS. ADVISORS LP (610,970 shares), IRIDIAN ASSET MANAGEMENT LLC/CT (610,064 shares), and GEODE CAPITAL MANAGEMENT, LLC (507,485 shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.